Giuseppe Banna gives a really wonderful talk in Athens in a session chaired by superstars Jarushka Naidoo Gil Morgan OncoAlert thanks to Giannis Mountzios for a great meeting! Marinos Tsiatas Marita Lykka MD Vivek Subbiah, MD Nathan A. Pennell MD, PhD, FASCO ΕΛΛΟΚ ANASTASIOS KYRIAZOGLOU Myrto K. Moutafi Stephen V Liu, MD H. Jack West, MD ASCO

3rd Athenian Oncology Congress🇬🇷
The Debate Continues
Stage IIIA #NSCLC 🫁 #LungCancer
IO before, after or both?

Giannis Mountzios 🇬🇷discusses both sides of the debate between Jarushka Naidoo & Giuseppe Banna
Part 3️⃣of 3️⃣

LIVE at Athenian Onology Congress🇬🇷 #3rdAOC
Jarushka Naidoo 🇮🇪 Presenting on:

Current and Future Challenges in KRASG12C🧬Mutant #NSCLC 🫁 #LungCancer Treatment

KRAS is NOW Druggable💊
Tox concerns will affect timing & delivery combos

3rd Athenian Oncology Congress🇬🇷
The Debate Continues
Stage IIIA #NSCLC 🫁 #LungCancer
IO before, after or both?

Giuseppe Banna 🇬🇧 🇮🇹 on neo adjuvant chemo and immunotherapy

Part 2️⃣of 3️⃣

3rd Athenian Oncology Congress🇬🇷
The Debate Continues
Stage IIIA #NSCLC 🫁 #LungCancer
IO before, after or both?

Jarushka Naidoo 🇮🇪on adjuvant chemo and immunotherapy

The pendulum swings towards adjuvant tx

Part 2️⃣of 3️⃣
Giuseppe Banna next

3rd Athenian Oncology Congress🇬🇷

A pleasure to debate the management of stage IIIA single station N2 NSCLC in NSCLC- adjuvant🇮🇪 Jarushka Naidoo v neoadjuvant🇬🇧 Giuseppe Banna, & present the adjuvant argument 👇

Getting ready for the storm

Giannis Mountzios OncoAlert #LCSM

A great debate starts at the 3rd Athenian Oncology Congress🇬🇷 Jarushka Naidoo 🆚 Giuseppe Banna 🥊
Giannis Mountzios sets up the case:
Stage IIIA #NSCLC 🫁 #LungCancer
IO before, after or both?
Part 1️⃣of 3️⃣

1/3) Exciting developments in lung trials for 🇮🇪 patients! 👏 to teams in Trinity St James's Cancer Institute Beaumont RCSI Cancer Centre Cancer Trials Cork UL Hospitals & UH Galway whose efforts will bring new treatments to 10+ patients w/ small cell & non-small cell lung cancer

(...see next Tweets for details)

3/3) MK-7684A-008: The first first-line small cell study in 🇮🇪 for many years. It's for patients w/ newly diagnosed extensive-stage small cell lung cancer (more: bit.ly/3Dgh2DO)

Led in 🇮🇪 by Sinead Cuffe, it's in St James's, Beaumont & Cork - all referrals welcome!!

2/3) Krystal-7: For patients w/ advanced/metastatic non-small cell lung cancer w/ KRAS G12C mutation (full criteria: bit.ly/3F0sqoA)

Led in 🇮🇪 by Jarushka Naidoo the study opens in Beaumont, Cork, limerick & Galway - all referrals welcome!

Long-term outcomes Ph II Savolitinib in Chinese Pts w METexon 14-skipping+ NSCLC JTO & JTO CRR:

- 70pts (pulm sarcomatoid, PSC=25, other=45)
- ORR 47.1% DCR 81.4%
- mOS 12.5mo (PSC 10.6m)

Pulm sarcomatoid NSCLC remains an area of unmet need
OncoAlert #LCSM
jtocrr.org/article/S2666-…

Your OncoAlert network is proud to be Live Covering the 3rd Athenian Oncology Congress happening October 21-22, 2022 in Athens Greece🇬🇷

An Amazing line up Petros Grivas Giannis Mountzios Jarushka Naidoo Vivek Subbiah, MD Maria Vakalopoulou Sanjay Popat Paolo Tarantino Stephen V Liu, MD & many more!

Highly recommend referring to the Updated ESMO Clinical Practice Guideline Annals of Oncology on immune-related toxicity.

Includes new information on the range of specialized immunosuppressive agents that may be used for immune toxicity

OncoAlert #IOTox
annalsofoncology.org/article/S0923-…

Baseline autoAbs predict outcomes in adj melanoma⁩:

- 950pts: CM238 (ipi=408 nivo=157)+CM915 (nivo=190 ipi/nivo=195)
- ⬆️recur score predicts ⬇️RFS, ⬆️tox score predicts severe irAEs w nivo, ipi, ipi/nivo, validated for nivo

⁦OncoAlert⁩ #IOTox aacrjournals.org/clincancerres/…

Great talk #SMR2022 by florentina dimitriou dissecting cytokines and pbmc phenotypes associated with increased iraes - IL17a in particular elevated with ⬆️ activation th17 cells- IL17 inhibition could be a potential therapeutic

Breathtaking picture depicting ICI-myocarditis in collaboration w/ Drs. Lin & Yang at MD Anderson Cancer Center! Green represents immune infiltrates in the heart. For the first time, we are beginning to understand why sex differences occur in myocarditis! #CardioOnc #CardioImmunology

Ph II trial TAK-228 (TORC1/2 inhib) in squam nsclc:

- 3 cohorts: NFE2L2-mt, KEAP1-mt, KRAS/KEAP1 or NFE2L2
- ORR in NFE2L2-mt: 25% (3/12), mPFS 8.9mo
- 32% g3 hyperglycemia

targeted thx finally coming to squamous nsclc? hope so

#LCSM ⁦OncoAlert⁩ jto.org/article/S1556-…

OncoAlert 3rd Athenian Oncology congress #3rdAOC to be held in Athens 21-22 October. 2 days full of science and discussion with a stellar faculty including international experts!
#LCSM #some
Register:
events.gr/el/events/even…«improving-cancer-care-by-opening-therapeutic-avenues»

#TSJCIConference

Super talk Anthony Letai MD PhD on anti-apoptotic approaches, &mitochondrial-apoptosis via BH3 profiling

?Perhaps rationale for drug combos is simpler than we think, &pushing a cell ‘over the edge’ through ⬆️apoptosis, is all we need

Trinity St James's Cancer Institute Irish Immunology